Richard B. Pearson

17.9k total citations · 5 hit papers
136 papers, 12.4k citations indexed

About

Richard B. Pearson is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Richard B. Pearson has authored 136 papers receiving a total of 12.4k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Molecular Biology, 30 papers in Oncology and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Richard B. Pearson's work include Protein Kinase Regulation and GTPase Signaling (34 papers), PI3K/AKT/mTOR signaling in cancer (27 papers) and RNA modifications and cancer (21 papers). Richard B. Pearson is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (34 papers), PI3K/AKT/mTOR signaling in cancer (27 papers) and RNA modifications and cancer (21 papers). Richard B. Pearson collaborates with scholars based in Australia, United States and Switzerland. Richard B. Pearson's co-authors include Bruce E. Kemp, Ross D. Hannan, Katherine M. Hannan, Grant A. McArthur, Wayne A. Phillips, Patrick B. Dennis, Elaine Sanij, Karen E. Sheppard, Anthony R. Means and Briony E. Cristiano and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Richard B. Pearson

135 papers receiving 12.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

[3] Protein kinase phosphorylation site sequences and consensus specificity motifs: Tabulations

1991 942 citations Richard B. Pearson, Bruce E. Kemp profile →
Protein kinase recognition sequence motifs

1990 910 citations Bruce E. Kemp, Richard B. Pearson profile →
Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

2004 740 citations Ian Campbell, Briony E. Cristiano et al. Cancer Research profile →
A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase.

1986 558 citations Bruce E. Kemp, Richard B. Pearson et al. profile →
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

2021 214 citations Jian Kang, Natalie Brajanovski et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Richard B. Pearson	9.6k	2.1k	1.5k	1.3k	922	136	12.4k
Marcelo G. Kazanietz	9.9k 1.0×	2.0k 1.0×	2.3k 1.5×	1.1k 0.9×	922 1.0×	192	13.2k
Nick Morrice	10.5k 1.1×	1.5k 0.7×	1.8k 1.2×	1.0k 0.8×	902 1.0×	113	13.1k
Gilles Pagès	7.2k 0.8×	2.2k 1.1×	1.1k 0.7×	2.1k 1.7×	852 0.9×	173	11.3k
Takao Hamakubo	6.6k 0.7×	1.0k 0.5×	1.1k 0.7×	1.3k 1.0×	965 1.0×	237	10.7k
Anton Wellstein	6.1k 0.6×	2.1k 1.0×	2.1k 1.4×	1.6k 1.3×	456 0.5×	223	9.4k
Edward Y. Skolnik	7.5k 0.8×	1.6k 0.8×	2.1k 1.4×	668 0.5×	763 0.8×	84	11.2k
Simon J. Cook	8.3k 0.9×	2.1k 1.0×	1.4k 0.9×	1.1k 0.9×	666 0.7×	131	10.9k
Michael Jaye	8.7k 0.9×	1.5k 0.7×	2.6k 1.7×	1.5k 1.2×	594 0.6×	114	12.0k
Yoel Kloog	6.8k 0.7×	1.7k 0.8×	1.2k 0.8×	966 0.8×	1.4k 1.6×	241	10.0k
Marsha Rich Rosner	7.9k 0.8×	1.8k 0.9×	1.2k 0.8×	1.4k 1.1×	1.8k 2.0×	178	11.3k

Countries citing papers authored by Richard B. Pearson

Since Specialization

Citations

This map shows the geographic impact of Richard B. Pearson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard B. Pearson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard B. Pearson more than expected).

Fields of papers citing papers by Richard B. Pearson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard B. Pearson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard B. Pearson. The network helps show where Richard B. Pearson may publish in the future.

Co-authorship network of co-authors of Richard B. Pearson

This figure shows the co-authorship network connecting the top 25 collaborators of Richard B. Pearson. A scholar is included among the top collaborators of Richard B. Pearson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard B. Pearson. Richard B. Pearson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Tianpei, Maria Doyle, Angela Pizzolla, et al.. (2023). Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironments. Nature Communications. 14(1). 2697–2697. 38 indexed citations

Zhu, Haoran, Keefe T. Chan, Anna Trigos, et al.. (2022). Cystathionine-β-synthase is essential for AKT-induced senescence and suppresses the development of gastric cancers with PI3K/AKT activation. eLife. 11. 24 indexed citations

Lawrence, Mitchell G., Laura H. Porter, David Pook, et al.. (2021). CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Molecular Cancer Therapeutics. 20(11). 2140–2150. 17 indexed citations

Peddigari, Suresh, Carol A. Mercer, Virginia Amador, et al.. (2021). Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death. Blood. 137(24). 3351–3364. 17 indexed citations

Kusnadi, Eric, Anna Trigos, Carleen Cullinane, et al.. (2020). Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis. The EMBO Journal. 39(21). e105111–e105111. 28 indexed citations

Gao, Jixuan, MoonSun Jung, Chelsea Mayoh, et al.. (2020). Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression. Cancer Research. 80(17). 3706–3718. 18 indexed citations

Khot, Amit, Natalie Brajanovski, Donald P. Cameron, et al.. (2019). First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. Cancer Discovery. 9(8). 1036–1049. 132 indexed citations

Diesch, Jeannine, Megan J. Bywater, Elaine Sanij, et al.. (2019). Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation. Communications Biology. 2(1). 39–39. 32 indexed citations

Khot, Amit, Natalie Brajanovski, Donald P. Cameron, et al.. (2017). RNA Polymerase 1 Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Malignancies: Results of a Phase I First in Human Study. Blood. 130. 3835–3835. 2 indexed citations

10.

Au‐Yeung, George, Walid J. Azar, Thomas J. Mitchell, et al.. (2016). Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clinical Cancer Research. 23(7). 1862–1874. 100 indexed citations

11.

Rebello, Richard J., Eric Kusnadi, Donald P. Cameron, et al.. (2016). The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. Clinical Cancer Research. 22(22). 5539–5552. 61 indexed citations

12.

Chan, Keefe T., Lassi Paavolainen, Katherine M. Hannan, et al.. (2016). Combining High-Content Imaging and Phenotypic Classification Analysis of Senescence-Associated Beta-Galactosidase Staining to Identify Regulators of Oncogene-Induced Senescence. Assay and Drug Development Technologies. 14(7). 416–428. 8 indexed citations

13.

Rebello, Richard J., Eric Kusnadi, Donald P. Cameron, et al.. (2016). The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer. European Journal of Cancer. 61. S167–S167. 10 indexed citations

14.

Devlin, Jennifer R., Katherine M. Hannan, Nadine Hein, et al.. (2015). Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. Cancer Discovery. 6(1). 59–70. 91 indexed citations

15.

Sheppard, Karen E., et al.. (2013). Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer. Clinical Cancer Research. 19(6). 1411–1421. 51 indexed citations

16.

Wall, Meaghan, Gretchen Poortinga, Kym L. Stanley, et al.. (2012). The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ- Myc Lymphoma by Restoring Oncogene-Induced Senescence. Cancer Discovery. 3(1). 82–95. 52 indexed citations

17.

Kinross, Kathryn M., Karen E. Sheppard, Richard B. Pearson, & Wayne A. Phillips. (2012). Targeting cancer with PI3K pathway inhibitors: who to aim at?. Translational Cancer Research. 1(2). 119–121. 2 indexed citations

18.

Jastrzebski, Katarzyna, et al.. (2007). Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors. 25(4). 209–226. 186 indexed citations

19.

Cristiano, Briony E., Katherine M. Hannan, Ian Campbell, et al.. (2006). A Specific Role for AKT3 in the Genesis of Ovarian Cancer through Modulation of G2-M Phase Transition. Cancer Research. 66(24). 11718–11725. 84 indexed citations

20.

Kemp, Bruce E., Richard B. Pearson, James R. Woodgett, & Pinchas Cohen. (1985). SUBSTRATE-SPECIFICITY OF A MULTIFUNCTIONAL CALMODULIN-DEPENDENT PROTEIN-KINASE. Discovery Research Portal (University of Dundee). 44(3). 1718. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact